Molecular Pathology in Adult Gliomas: Diagnostic, Prognostic, and Predictive Markers

Overview

Journal Lancet Neurol

Specialty Neurology

Date 2010 Jul 9

PMID 20610347

Citations 127

Authors

Michael Jansen

Stephen Yip

David N Louis

Affiliations

Soon will be listed here.

Abstract

Over the past 10 years, there has been an increasing use of molecular markers in the assessment and management of adult malignant gliomas. Some molecular signatures are used diagnostically to help pathologists classify tumours, whereas others are used to estimate prognosis for patients. Most crucial, however, are those markers that are used to predict response to certain therapies, thereby directing clinicians to a particular treatment while avoiding other potentially deleterious therapies. Recently, large-scale genome-wide surveys have been used to identify new biomarkers that have been rapidly developed as diagnostic and prognostic tools. Given these developments, the pace of discovery of new molecular assays will quicken to facilitate personalised medicine in the setting of malignant glioma.

Citing Articles

Predictive and Prognostic Significance of Molecular Biomarkers in Glioblastoma.

Shah S, Nag A, Sachithanandam S, Lucke-Wold B Biomedicines. 2025; 12(12.

PMID: 39767571 PMC: 11727522. DOI: 10.3390/biomedicines12122664.

Unraveling the role of PBK in glioblastoma: from molecular mechanisms to therapeutic targets.

Zhang Y, Luan M Ann Med Surg (Lond). 2024; 86(12):7147-7154.

PMID: 39649886 PMC: 11623866. DOI: 10.1097/MS9.0000000000002708.

Ethanol extract of Vanilla planifolia stems reduces PAK6 expression and induces cell death in glioblastoma cells.

Chang H, Chang A, Tsai B, Chen Y, Wu S, Chen L J Cell Mol Med. 2024; 28(17):e70065.

PMID: 39233332 PMC: 11374694. DOI: 10.1111/jcmm.70065.

The Comprehensive Analysis of m6A-Associated Anoikis Genes in Low-Grade Gliomas.

Zheng H, Zhao Y, Zhou H, Tang Y, Xie Z Brain Sci. 2023; 13(9).

PMID: 37759912 PMC: 10527396. DOI: 10.3390/brainsci13091311.

Caspase-3 in glioma indicates an unfavorable prognosis by involving surrounding angiogenesis and tumor cell repopulation.

Feng X, Zhu F, Dai L, Liu X, Shao L, Hao L J Neurooncol. 2023; 163(2):313-325.

PMID: 37195411 DOI: 10.1007/s11060-023-04339-x.

References

Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M . Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?. Clin Cancer Res. 2007; 13(23):6933-7. DOI: 10.1158/1078-0432.CCR-07-0573. View

van den Bent M, Carpentier A, Brandes A, Sanson M, Taphoorn M, Bernsen H . Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of.... J Clin Oncol. 2006; 24(18):2715-22. DOI: 10.1200/JCO.2005.04.6078. View

Abrey L, Louis D, Paleologos N, Lassman A, Raizer J, Mason W . Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol. 2007; 9(3):314-8. PMC: 1907408. DOI: 10.1215/15228517-2007-002. View

Agosti R, Leuthold M, Gullick W, YASARGIL M, Wiestler O . Expression of the epidermal growth factor receptor in astrocytic tumours is specifically associated with glioblastoma multiforme. Virchows Arch A Pathol Anat Histopathol. 1992; 420(4):321-5. DOI: 10.1007/BF01600211. View

Gerstner E, Yip S, Wang D, Louis D, Iafrate A, Batchelor T . Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology. 2009; 73(18):1509-10. PMC: 2779003. DOI: 10.1212/WNL.0b013e3181bf9907. View

Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D . Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2009; 20(1):245-54. PMC: 8094636. DOI: 10.1111/j.1750-3639.2009.00352.x. View

SUGAWA N, Ekstrand A, James C, Collins V . Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A. 1990; 87(21):8602-6. PMC: 55005. DOI: 10.1073/pnas.87.21.8602. View

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A . Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009; 118(4):469-74. DOI: 10.1007/s00401-009-0561-9. View

Jaeckle K, Eyre H, Townsend J, Schulman S, Knudson H, Belanich M . Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998; 16(10):3310-5. DOI: 10.1200/JCO.1998.16.10.3310. View

10.

Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman J, Esteller M . Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol. 2006; 83(1):91-3. DOI: 10.1007/s11060-006-9292-0. View

11.

Jones D, Kocialkowski S, Liu L, Pearson D, Backlund L, Ichimura K . Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008; 68(21):8673-7. PMC: 2577184. DOI: 10.1158/0008-5472.CAN-08-2097. View

12.

Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D . Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006; 24(18):2707-14. DOI: 10.1200/JCO.2005.04.3414. View

13.

Ducray F, Idbaih A, De Reynies A, Bieche I, Thillet J, Mokhtari K . Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer. 2008; 7:41. PMC: 2415112. DOI: 10.1186/1476-4598-7-41. View

14.

Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, LeJeune J . Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004; 22(15):3133-8. DOI: 10.1200/JCO.2004.10.169. View

15.

Cairncross G, Jenkins R . Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J. 2008; 14(6):352-7. DOI: 10.1097/PPO.0b013e31818d8178. View

16.

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

17.

Jeuken J, Cornelissen S, Vriezen M, Dekkers M, Errami A, Sijben A . MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest. 2007; 87(10):1055-65. DOI: 10.1038/labinvest.3700664. View

18.

Stommel J, Kimmelman A, Ying H, Nabioullin R, Ponugoti A, Wiedemeyer R . Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007; 318(5848):287-90. DOI: 10.1126/science.1142946. View

19.

Dei Tos A, Ellis I . Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?. Eur J Cancer. 2005; 41(10):1383-92. DOI: 10.1016/j.ejca.2005.03.018. View

20.

van den Bent M, Dubbink H, Sanson M, van der Lee-Haarloo C, Hegi M, Jeuken J . MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009; 27(35):5881-6. PMC: 2793037. DOI: 10.1200/JCO.2009.24.1034. View